Denali Therapeutics Inc. (DNLI) Tops Q4 EPS by 17c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.67), $0.17 better than the analyst estimate of ($0.84).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Flux Power Holdings (FLUX) PT Lowered to $1.60 at Roth/MKM
• UBS says bull market has further to run